The alirocumab group , as compared with the placebo group , had higher rates of injection-site reactions ( @ % vs. @ % ) , myalgia ( @ % vs. @ % ) , neurocognitive events ( @ % vs. @ % ) , and ophthalmologic events ( @ % vs. @ % ) .